BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32058031)

  • 1. Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma.
    Buechler C; Aslanidis C
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 May; 1865(5):158658. PubMed ID: 32058031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipidomic Profiles of Plasma Exosomes Identify Candidate Biomarkers for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis.
    Sanchez JI; Jiao J; Kwan SY; Veillon L; Warmoes MO; Tan L; Odewole M; Rich NE; Wei P; Lorenzi PL; Singal AG; Beretta L
    Cancer Prev Res (Phila); 2021 Oct; 14(10):955-962. PubMed ID: 34253566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrosis Index Based on 4 Factors (FIB-4) Predicts Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis C Virus (HCV) Patients.
    Li X; Xu H; Gao P
    Med Sci Monit; 2019 Sep; 25():7243-7250. PubMed ID: 31558693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum lipid profiling of patients with chronic hepatitis B, cirrhosis, and hepatocellular carcinoma by ultra fast LC/IT-TOF MS.
    Chen S; Yin P; Zhao X; Xing W; Hu C; Zhou L; Xu G
    Electrophoresis; 2013 Oct; 34(19):2848-56. PubMed ID: 24228263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceramide and polyunsaturated phospholipids are strongly reduced in human hepatocellular carcinoma.
    Krautbauer S; Meier EM; Rein-Fischboeck L; Pohl R; Weiss TS; Sigruener A; Aslanidis C; Liebisch G; Buechler C
    Biochim Biophys Acta; 2016 Nov; 1861(11):1767-1774. PubMed ID: 27570113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.
    Di Poto C; Ferrarini A; Zhao Y; Varghese RS; Tu C; Zuo Y; Wang M; Nezami Ranjbar MR; Luo Y; Zhang C; Desai CS; Shetty K; Tadesse MG; Ressom HW
    Cancer Epidemiol Biomarkers Prev; 2017 May; 26(5):675-683. PubMed ID: 27913395
    [No Abstract]   [Full Text] [Related]  

  • 7. RASSF1A and SOCS1 genes methylation status as a noninvasive marker for hepatocellular carcinoma.
    Pasha HF; Mohamed RH; Radwan MI
    Cancer Biomark; 2019; 24(2):241-247. PubMed ID: 30689554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Value of Systemic Cholesteryl Ester/Free Cholesterol Ratio in Hepatocellular Carcinoma.
    Krautbauer S; Weiss TS; Wiest R; Schacherer D; Liebisch G; Buechler C
    Anticancer Res; 2017 Jul; 37(7):3527-3535. PubMed ID: 28668842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features of aflatoxin B1-exposed patients with liver cancer and the molecular mechanism of aflatoxin B1 on liver cancer cells.
    Zhou R; Liu M; Liang X; Su M; Li R
    Environ Toxicol Pharmacol; 2019 Oct; 71():103225. PubMed ID: 31376682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal lipid and lipoprotein patterns in liver cirrhosis with and without hepatocellular carcinoma.
    Ahaneku JE; Taylor GO; Olubuyide IO; Agbedana EO
    J Pak Med Assoc; 1992 Nov; 42(11):260-3. PubMed ID: 1336073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma lipidomic fingerprinting to distinguish among hepatitis C-related hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis C using MALDI-TOF mass spectrometry: a pilot study.
    Passos-Castilho AM; Lo Turco E; Ferraz ML; Matos C; Silva I; Parise E; Pilau E; Gozzo F; Granato C
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):43-9. PubMed ID: 25822433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry.
    Passos-Castilho AM; Carvalho VM; Cardozo KH; Kikuchi L; Chagas AL; Gomes-Gouvêa MS; Malta F; de Seixas-Santos Nastri AC; Pinho JR; Carrilho FJ; Granato CF
    BMC Cancer; 2015 Dec; 15():985. PubMed ID: 26680993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum level of soluble vascular cell adhesion molecule in patients with hepatocellular carcinoma and its association with severity of liver disease.
    Diaz-Sanchez A; Matilla A; Nuñez O; Rincon D; Lorente R; Lo Iacono O; Merino B; Hernando A; Campos R; Clemente G; Bañares R
    Ann Hepatol; 2013; 12(2):236-47. PubMed ID: 23396735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocarcinogenesis and ceramide/cholesterol metabolism.
    Morales A; Mari M; Garcia-Ruiz C; Colell A; Fernandez-Checa JC
    Anticancer Agents Med Chem; 2012 May; 12(4):364-75. PubMed ID: 22043999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue and serum metabolomic phenotyping for diagnosis and prognosis of hepatocellular carcinoma.
    Han J; Han ML; Xing H; Li ZL; Yuan DY; Wu H; Zhang H; Wang MD; Li C; Liang L; Song YY; Xu AJ; Wu MC; Shen F; Xie Y; Yang T
    Int J Cancer; 2020 Mar; 146(6):1741-1753. PubMed ID: 31361910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
    Tátrai P
    Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
    Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
    Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Significance of glypican-3 immunohistochemistry in diagnosis of hepatocellular carcinoma].
    Yip YC; Wang FH; Vong HT; Zhang M; Wen JM
    Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):626-9. PubMed ID: 22177248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse cirrhosis-like hepatocellular carcinoma: a clinically and radiographically undetected variant mimicking cirrhosis.
    Jakate S; Yabes A; Giusto D; Naini B; Lassman C; Yeh MM; Ferrell LD
    Am J Surg Pathol; 2010 Jul; 34(7):935-41. PubMed ID: 20463569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.